

Sheet 1 of 1

FORM PTO 449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.: CV01379K	SERIAL NO.: 10/057,646
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use several sheets if necessary)		APPLICANT: Harry R. Davis et al.	
		FILING DATE: January 25, 2002	GROUP: 1614

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
S	AB	10/057,534	01/25/02	Harry R. Davis et al.			
	AC	10/057,629	01/25/02	Harry R. Davis			
	AD	10/154,106	05/22/02	Harry R. Davis et al.			
	AE	10/057,323	01/25/02	Harry R. Davis et al.			
	AF	10/136,968	05/01/02	Wing-Kee Philip Cho et al.			
	AG	10/057,339	01/25/02	Teddy Kosoglou et al.			
	AH	10/247,032	09/19/02	Harry R. Davis			
	AI	10/056,680	01/25/02	Teddy Kosoglou et al.			
	AK	10/247,099	09/19/02	Harry R. Davis et al.			
	AL	10/247,085	09/19/02	John T. Strony			
	AM	10/247,095	09/19/02	Harry R. Davis			
	AN	10/246,996	09/19/02	Alexandre P. Lebeaut et al.			
	AO	10/247,397	09/19/02	Harry R. Davis et al.			
	AP	10/166,942	06/11/02	Anima Ghosal et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES	NO
	AQ							
	AR							
	AS							
	AT							
	AU							
	AV							
	AW							

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AX	ZETIA™ (ezetimibe) Tablets Package Insert (Merck/Schering-Plough Pharmaceuticals) (October 2002)
S	AY	Schering-Plough Reports Financial Results for 2003 Fourth Quarter, Full Year, Monday, January 26, 6:33 am ET
	AZ	
	BA	
	BB	
	BC	

EXAMINER  S. ✓	DATE CONSIDERED  4/24/04
----------------------	--------------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 1 of 1

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.:  
**CV01379K**APPLICATION NO.:  
**10/057,646****INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**APPLICANT:  
**Harry R. Davis et al.***(Use several sheets if necessary)*FILING DATE:  
**01/25/2002**GROUP:  
**1614****U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
<i>S</i>	AA	6,030,990	02/29/00	Maeda et al.			
<i>S</i>	AB	6,166,049	12/26/00	Smith et al.			
<i>S</i>	AC	2003/0153541	08/14/03	Dudley et al.			

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION	
							YES	NO
<i>S</i>	AC	WO 01/14351	03/01/01	PCT				
<i>S</i>	AD	WO 01/34148	05/17/01	PCT				
	AE	WO 01/60807	08/23/01	PCT				
	AF	WO 02/064094	08/22/02	PCT				
	AG	WO 02/08188	01/31/02	PCT				
	AH	WO 02/26729	04/04/02	PCT				
	AI	WO 03/039542	05/15/03	PCT				
	AJ	WO 03/074101	09/12/03	PCT				
<i>S</i>	AK	WO 03/088962	10/30/03	PCT				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

<i>S</i>	AL	Sorbera et al., Netoglitzazone, <i>Drugs of the Future</i> , 2002, 27(2): 132-139
<i>S</i>	AM	Michel Farnier, Nouvelles approches médicamenteuses dans le traitement des dyslipidémies, <i>MT Endocrinologie</i> , 2002, 4:252-259
<i>S</i>	AN	Berger et al., Physiological and Therapeutic Roles of Peroxisome Proliferator-Activated Receptors, <i>Diabetes Technology &amp; Therapeutics</i> , 2002, 4:163-174

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.